Watson to Host Third Quarter 2012 Earnings Conference Call and Webcast

PARSIPPANY, N.J., Oct. 22, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that the Company intends to release its third quarter 2012 financial results on November 1, 2012, prior to the open of the U.S. financial markets.  The Company will host a conference call and webcast at 8:30 a.m. Eastern Time on November 1, 2012 to discuss its financial results and provide an update on the Company's outlook for 2012.  The dial-in number to access the call is U.S./Canada (877) 251-7980, International (706) 643-1573, and the Conference ID is 37197625.

A taped replay of the conference call will also be available beginning approximately two hours after the call's conclusion and will remain available through 12:00 midnight Eastern Time on November 15, 2012.  The replay may be accessed by dialing (855) 859-2056 and entering pass code 37197625.  From international locations, the replay may be accessed by dialing (404) 537-3406 and entering the same pass code.  To access the webcast, go to Watson's Investor Relations Web site at http://ir.watson.com.  A replay of the webcast will also be available.

About Watson Pharmaceuticals, Inc.
Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. The Company is also developing biosimilar products in Women's Health and Oncology.  Additionally, Watson distributes generic and branded pharmaceuticals through its Anda, Inc. distribution business. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )

SOURCE Watson Pharmaceuticals, Inc.